Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

LAG-3 and PD-1 blockade raises the bar for melanoma

Combination of approved immune checkpoint inhibitors has shown remarkable efficacy in the treatment of melanoma, but at the cost of high toxicity. After years of intensive research, inhibitors of the immune checkpoint molecule LAG-3 are now demonstrating promising results and favorable toxicity profiles in clinical trials in combination with inhibition of the checkpoint molecule PD-1.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Comparison of the combinations ipilimumab plus nivolumab and relatlimab plus nivolumab.

References

  1. Hodi, F. S. et al. N. Engl. J. Med. 363, 711–723 (2010).

    Article  CAS  Google Scholar 

  2. Robert, C. et al. N. Engl. J. Med. 372, 2521–2532 (2015).

    Article  CAS  Google Scholar 

  3. Robert, C. et al. N. Engl. J. Med. 372, 320–330 (2015).

    Article  CAS  Google Scholar 

  4. Larkin, J. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1910836 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tawbi, H. A. et al. N. Engl. J. Med. 379, 722–730 (2018).

    Article  CAS  Google Scholar 

  6. Zimmer, L. et al. Lancet 395, 1558–1568 (2020).

    Article  CAS  Google Scholar 

  7. Blank, C. U. et al. Nat. Med. 24, 1655–1661 (2018).

    Article  CAS  Google Scholar 

  8. Maruhashi, T., Sugiura, D., Okazaki, I. & Okazaki, T. J. Immunother. Cancer 8, e001014 (2020).

    Article  Google Scholar 

  9. He, Y. et al. J. Thorac. Oncol. 12, 814–823 (2017).

    Article  Google Scholar 

  10. Woo, S.-R. et al. Cancer Res. 72, 917–927 (2012).

    Article  CAS  Google Scholar 

  11. Grosso, J. F. et al. J. Clin. Invest. 117, 3383–3392 (2007).

    Article  CAS  Google Scholar 

  12. Huang, R.-Y. et al. Oncotarget 6, 27359–27377 (2015).

    Article  Google Scholar 

  13. Ascierto, P. A. et al. Ann. Oncol. 28, v611–v612 (2017).

    Article  Google Scholar 

  14. Lipson, E. J. et al. J. Clin. Oncol. 39, 9503–9503 (2021).

    Article  Google Scholar 

  15. Amaria, R. N. et al. J. Clin. Oncol. 39, 9502–9502 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Caroline Robert.

Ethics declarations

Competing interests

The author is a consultant for Bristol Myers Squibb, Merck Sharp & Dohme, Merck, Novartis, Roche, AstraZeneca, Pierre Fabre and Sanofi.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Robert, C. LAG-3 and PD-1 blockade raises the bar for melanoma. Nat Cancer 2, 1251–1253 (2021). https://doi.org/10.1038/s43018-021-00276-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-021-00276-8

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer